Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: New prospects for an old drug

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 8, 2012, Pages 1884-1894

  Mastrangelo, Eloise ^a   Pezzullo, Margherita ^a   De burghgraeve, Tine ^b   Kaptein, Suzanne ^b   Pastorino, Boris ^c   Dallmeier, Kai ^b   De lamballerie, Xavier ^c   Neyts, Johan ^b   Hanson, Alicia M ^d   Frick, David N ^d   Bolognesi, Martino ^a   Milani, Mario ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c Aix Marseille University IRD 190 Inserm 1207   (France)

^d UNIVERSITY OF WISCONSIN MILWAUKEE   (United States)

Author keywords

Antiviral drug discovery; Flavivirus helicase inhibition; In silico docking; New use of existing drug; Structure based drug design

Indexed keywords

HELICASE; IVERMECTIN; NONSTRUCTURAL PROTEIN 3;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; CATALYSIS; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; IN VITRO STUDY; JAPANESE ENCEPHALITIS VIRUS; KUNJIN VIRUS; MOLECULAR DOCKING; NONHUMAN; PROTEIN EXPRESSION; TICK BORNE ENCEPHALITIS FLAVIVIRUS; VIRUS MUTATION; VIRUS REPLICATION; YELLOW FEVER FLAVIVIRUS;

ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; DENGUE VIRUS; ENCEPHALITIS VIRUSES, JAPANESE; ENCEPHALITIS VIRUSES, TICK-BORNE; ENZYME INHIBITORS; IVERMECTIN; MOLECULAR DYNAMICS SIMULATION; RNA HELICASES; SERINE ENDOPEPTIDASES; VERO CELLS; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION; YELLOW FEVER VIRUS;

EID: 84864523421     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks147     Document Type: Article

References (45)

1. Gould EA, Solomon T. Pathogenic flaviviruses. Lancet 2008; 371: 500-9.
2. Monath TP. Yellow fever: an update. Lancet Infect Dis 2001; 1: 11-20.
3. Staples JE, Monath TP. Yellow fever: 100 years of discovery. JAMA 2008; 300: 960-2.
4. Barrett AD, Higgs S. Yellow fever: a disease that has yet to be conquered. Annu Rev Entomol 2007; 52: 209-29.
5. Ellis BR, Barrett AD. The enigma of yellow fever in East Africa. Rev Med Virol 2008; 18: 331-46.
6. Vasilakis N, Weaver SC. The history and evolution of human dengue emergence. Adv Virus Res 2008; 72: 1-76.
7. Guzman MG, Kouri G. Dengue haemorrhagic fever integral hypothesis: confirming observations, 1987-2007. Trans R Soc Trop Med Hyg 2008; 102: 522-3.
8. Petersen LR, Hayes EB. West Nile virus in the Americas. Med Clin North Am 2008; 92: 1307-22, ix.
9. Bartholomeusz AI, Wright PJ. Synthesis of dengue virus RNA in vitro: initiation and the involvement of proteins NS3 and NS5. Arch Virol 1993; 128: 111-21.
10. Caruthers JM, McKay DB. Helicase structure and mechanism. Curr Opin Struct Biol 2002; 12: 123-33.
11. Luo D, Xu T, Watson RP et al. Insights into RNA unwinding and ATP hydrolysis by the flavivirus NS3 protein. EMBO J 2008; 27: 3209-19.
12. Bollati M, Alvarez K, Assenberg R et al. Structure and functionality in flavivirus NS-proteins: perspectives for drug design. Antiviral Res 2010; 87: 125-48.
13. Manfroni G, Paeshuyse J, Massari S et al. Inhibition of subgenomic hepatitis C virus RNA replication by acridone derivatives: identification of an NS3 helicase inhibitor. J Med Chem 2009; 52: 3354-65.
14. De Palma AM, Vliegen I, De Clercq E et al. Selective inhibitors of picornavirus replication. Med Res Rev 2008; 28: 823-84.
15. Huggins JW. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev Infect Dis 1989; 11(Suppl. 4): S750-61.
16. Borowski P, Mueller O, Niebuhr A et al. ATP-binding domain of NTPase/ helicase as a target for hepatitis C antiviral therapy. Acta Biochim Pol 2000; 47: 173-80.
17. Sbrana E, Xiao SY, Guzman H et al. Efficacy of post-exposure treatment of yellow fever with ribavirin in a hamster model of the disease. Am J Trop Med Hyg 2004; 71: 306-12.
18. Zhang N, Chen HM, Koch V et al. Ring-expanded (" fat" ) nucleoside and nucleotide analogues exhibit potent in vitro activity against Flaviviridae NTPases/helicases, including those of the West Nile virus, hepatitis C virus, and Japanese encephalitis virus. J Med Chem 2003; 46: 4149-64.
19. Borowski P, Niebuhr A, Mueller O et al. Purification and characterization of West Nile virus nucleoside triphosphatase (NTPase)/ helicase: evidence for dissociation of the NTPase and helicase activities of the enzyme. J Virol 2001; 75: 3220-9.
20. Gozdek A, Zhukov I, Polkowska A et al. NS3 peptide, a novel potent hepatitis C virus NS3 helicase inhibitor: its mechanism of action and antiviral activity in the replicon system. Antimicrob Agents Chemother 2008; 52: 393-401.
21. Mastrangelo E, Milani M, Bollati M et al. Crystal structure and activity of Kunjin virus NS3 helicase; protease and helicase domain assembly in the full length NS3 protein. J Mol Biol 2007; 372: 444-55.
22. Chu PW, Westaway EG. Replication strategy of Kunjin virus: evidence for recycling role of replicative form RNA as template in semiconservative and asymmetric replication. Virology 1985; 140: 68-79.
23. Scherret JH, Poidinger M, Mackenzie JS et al. The relationships between West Nile and Kunjin viruses. Emerg Infect Dis 2001; 7: 697-705.
24. Morris GM, Goodsell DS, Halliday RS et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 1998; 19: 1639-62.
25. Singh UC, Kollman PA. An approach to computing electrostatic charges for molecules. J Comput Chem 1984; 5: 129-45.
26. Goodford PJ. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J Med Chem 1985; 28: 849-57.
27. Gasteiger J, Marsili M. A new model for calculating atomic charges in molecules. Tetrahedron Lett 1978; 34: 3181-4.
28. Mastrangelo E, Bollati M, Milani M et al. Preliminary crystallographic characterization of an RNA helicase from Kunjin virus. Acta Crystallogr Sect F Struct Biol Cryst Commun 2006; 62: 876-9.
29. De Colibus L, Speroni S, Coutard B et al. Purification and crystallization of Kokobera virus helicase. Acta Crystallogr Sect F Struct Biol Cryst Commun 2007; 63: 193-5.
30. Wu J, Bera AK, Kuhn RJ et al. Structure of the flavivirus helicase: implications for catalytic activity, protein interactions, and proteolytic processing. J Virol 2005; 79: 10268-77.
31. Boguszewska-Chachulska AM, Krawczyk M, Stankiewicz A et al. Direct fluorometric measurement of hepatitis C virus helicase activity. FEBS Lett 2004; 567: 253-8.
32. Belon CA, High YD, Lin TI et al. Mechanism and specificity of a symmetrical benzimidazolephenylcarboxamide helicase inhibitor. Biochemistry 2010; 49: 1822-32.
33. Kaptein SJ, De Burghgraeve T, Froeyen M et al. A derivate of the antibiotic doxorubicin is a selective inhibitor of dengue and yellow fever virus replication in vitro. Antimicrob Agents Chemother 2010; 54: 5269-80.
34. Velankar SS, Soultanas P, Dillingham MS et al. Crystal structures of complexes of PcrA DNA helicase with a DNA substrate indicate an inchworm mechanism. Cell 1999; 97: 75-84.
35. Vicens Q, Westhof E. Crystal structure of paromomycin docked into the eubacterial ribosomal decoding A site. Structure 2001; 9: 647-58.
36. Mukhopadhyay S, Kuhn RJ, Rossmann MG. A structural perspective of the flavivirus life cycle. Nat Rev Microbiol 2005; 3: 13-22.
37. Sampath A, Padmanabhan R. Molecular targets for flavivirus drug discovery. Antiviral Res 2009; 81: 6-15.
38. Mastrangelo E, Bolognesi M, Milani M. Flaviviral helicase: insights into the mechanism of action of a motor protein. Biochem Biophys Res Commun 2012; 417: 84-7.
39. Yin Z, Chen YL, Schul W et al. An adenosine nucleoside inhibitor of dengue virus. Proc Natl Acad Sci USA 2009; 106: 20435-9.
40. Xie X, Wang QY, Xu HY et al. Inhibition of dengue virus by targeting viral NS4B protein. J Virol 2011; 85: 11183-95.
41. Julander JG, Jha AK, Choi JA et al. Efficacy of 2'-C-methylcytidine against yellow fever virus in cell culture and in a hamster model. Antiviral Res 2010; 86: 261-7.
42. Julander JG, Shafer K, Smee DF et al. Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob Agents Chemother 2009; 53: 202-9.
43. Omura S. Ivermectin: 25 years and still going strong. Int J Antimicrob Agents 2008; 31: 91-8.
44. Geary TG. Ivermectin 20 years on: maturation of a wonder drug. Trends Parasitol 2005; 21: 530-2.
45. Cully DF, Vassilatis DK, Liu KK et al. Cloning of an avermectin-sensitive glutamate-gated chloride channel from Caenorhabditis elegans. Nature 1994; 371: 707-11.